EUVIMEDEUVIMED entdecken
Crossref

Integrated High-Throughput Screening and Large-Scale Isobolographic Analysis to Accelerate the Discovery of Radiosensitizers With Greater Selectivity for Cancer Cells

Pierre Verrelle, Pierre Gestraud, Florent Poyer, Adèle Soria, Sarah Tessier, Aurianne Lescure, Elodie Anthony, Maxime Corbé, Sophie Heinrich, Claire Beauvineau, Ludovic Chaput, Anton Granzhan und 5 weitere

International Journal of Radiation Oncology*Biology*Physics · 2024

DOI: 10.1016/j.ijrobp.2023.09.044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Pierre Verrelle und 16 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Institut Curie Hospital, Paris, France; Chemistry and Modelisation for the Biology of Cancer, CNRS UMR9187, INSERM U11…. Hauptthemen laut MEDLINE: Radiation-Sensitizing Agents, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: High-throughput screening (HTS) platforms have been widely used to identify candidate anticancer drugs and drug-drug combinations; however, HTS-based identification of new drug-ionizing radiation (IR) combinations has rarely been reported. Herein, we developed an integrated approach including cell-based HTS and computational large-scale isobolographic analysis to accelerate the identification of radiosensitizing compounds acting strongly and more specifically on cancer cells. METHODS AND MATERIALS: In a 384-well plate format, 160 compounds likely to interfere with the cell response to radiation were screened on human glioblastoma (U251-MG) and cervix carcinoma (ME-180) cell lines, as well as on normal fibroblasts (CCD-19Lu). After drug exposure, cells were irradiated or not and short-term cell survival was assessed by high-throughput cell microscopy. Computational large-scale dose-response and isobolographic approach were used to identify promising synergistic drugs radiosensitizing cancer cells rather than normal cells. Synergy of a promising compound was confirmed on ME-180 cells by an independent 96-well assay protocol, and finally, by the gold-standard colony forming assay. RESULTS: We retained 4 compounds synergistic at 2 isoeffects in U251-MG and ME-180 cell lines and 11 compounds synergistically effective in only one cancer cell line. Among these 15 promising radiosensitizers, 5 compounds showed limited toxicity combined or not with IR on normal fibroblasts. CONCLUSIONS: Overall, this study demonstrated that HTS chemoradiation screening together with large-scale computational analysis is an efficient tool to identify synergistic drug-IR combinations, with concomitant assessment of unwanted toxicity on normal fibroblasts. It sparks expectations to accelerate the discovery of highly desired agents improving the therapeutic index of radiation therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiation-Sensitizing AgentsAntineoplastic AgentsNeoplasmsFemaleHumansHigh-Throughput Screening AssaysEarly Detection of CancerCell LineCell Line, Tumor

Substanzen

Radiation-Sensitizing AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • Radiation Oncology Department, Institut Curie Hospital, Paris, France; Chemistry and Modelisation for the Biology of Cancer, CNRS UMR9187, INSERM U1196, Institut Curie, Université Paris Saclay, 91405 Orsay, France. Elec…
  • Chemistry and Modelisation for the Biology of Cancer, CNRS UMR9187, INSERM U1196, Institut Curie, Université Paris Saclay, 91405 Orsay, France.
  • Biophenics High-Content Screening Laboratory, Department of Translational Research, PSL Research University, PICT-IBiSa, Institut Curie Research Center, Paris, France.
  • Experimental Radiotherapy Platform (RadeXp), Translational Research Department, Institut Curie, Orsay, France; Inserm U1021-CNRS UMR 3347, Institut Curie, Paris Saclay University.
  • Bioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, Paris, France.
  • Bioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, Paris, France; BioCIS UMR8076, Université Paris-Saclay, Faculté de Pharmacie, Orsay, France.

Zitieren

APA

Verrelle, P., Gestraud, P., Poyer, F., Soria, A., Tessier, S., Lescure, A., Anthony, E., Corbé, M., Heinrich, S., Beauvineau, C., Chaput, L., Granzhan, A., Piguel, S., Perez, F., Teulade-Fichou, M. P., Megnin-Chanet, F., & Del Nery, E. (2024). Integrated High-Throughput Screening and Large-Scale Isobolographic Analysis to Accelerate the Discovery of Radiosensitizers With Greater Selectivity for Cancer Cells. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.09.044

Vancouver

Verrelle P, Gestraud P, Poyer F, Soria A, Tessier S, Lescure A, et al. Integrated High-Throughput Screening and Large-Scale Isobolographic Analysis to Accelerate the Discovery of Radiosensitizers With Greater Selectivity for Cancer Cells. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2023.09.044

BibTeX
@article{Verrelle2024,
  author = {Verrelle, Pierre and Gestraud, Pierre and Poyer, Florent and Soria, Adèle and Tessier, Sarah and Lescure, Aurianne and Anthony, Elodie and Corbé, Maxime and Heinrich, Sophie and Beauvineau, Claire and Chaput, Ludovic and Granzhan, Anton and Piguel, Sandrine and Perez, Franck and Teulade-Fichou, Marie-Paule and Megnin-Chanet, Frédérique and Del Nery, Elaine},
  title = {Integrated High-Throughput Screening and Large-Scale Isobolographic Analysis to Accelerate the Discovery of Radiosensitizers With Greater Selectivity for Cancer Cells},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  doi = {10.1016/j.ijrobp.2023.09.044}
}
Kostenlos starten →